Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy
- 1 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Pharmacy
- Vol. 42 (1), 158-166
- https://doi.org/10.1007/s11096-019-00953-w
Abstract
Background: The variability in the clinical response to clopidogrel treatment has been attributed to genetic factors, but the specific genes and other risk factors remain unclear. Objective: To investigate the incidence of high on-treatment platelet reactivity in coronary heart disease patients following clopidogrel therapy by analyzing the correlation between genetic polymorphisms and high on-treatment platelet reactivity. Setting: This study was conducted in the Chinese People’s Liberation Army (PLA) general hospital. Method: 578 patients with coronary heart disease undergoing percutaneous transluminal coronary intervention treatment were enrolled. They received dual antiplatelet therapy with aspirin (300 mg) plus clopidogrel (300 mg) over 24 h, or aspirin (100 mg/day) and clopidogrel (75 mg/day) over 3 days. Patients were divided into two groups according to the adenosine diphosphate inhibition rate. The follow-up lasted at least 12 months and adverse endpoint events were recorded. Main outcome measure: The single nucleotide polymorphisms were detected by MassArray genotyping system. Results: The incidence of HTPR was 15.74% in total, being higher in females than in males (24.29% vs. 13.01%, P < 0.01). Diabetes mellitus, homocysteine and high sensitivity C-reactive protein (hs-CRP) levels were significantly higher in the HTPR group than those in the non-HTPR group (P < 0.05). Polymorphisms of rs1057910 (OR 2.90, P = 0.003), rs2246709 (OR 0.69, P = 0.039), and rs776746 (OR 0.66, P = 0.034) were associated with the incidence of high on-treatment platelet reactivity. Female patients were prone to polymorphisms of rs1057910 (OR 3.24, P = 0.004) and rs776746 (OR 0.57, P = 0.025). Compared to non-high on-treatment platelet reactivity group, no differences in high reactivity group were observed with coexisting single nucleotide polymorphisms (14.6% vs. 14.8%, P > 0.05). The adverse endpoint events were significantly higher in the high on-treatment platelet reactivity group than in the non-treatment reactivity group. The survival analysis showed that high on-treatment platelet reactivity was significantly associated with the risk of the endpoint events (P = 0.0219). Conclusion: Gender (female), diabetes mellitus, high levels of homocysteine and hs-CRP were risk factors for high on-treatment platelet reactivity, and high reactivity was a strong predictor for adverse endpoint events in the coronary heart disease patients. The polymorphism of rs1057910 was a risk factor of high on-treatment platelet reactivity while rs2246709 and rs776746 polymorphisms were protective factors, and coexisting single nucleotide polymorphisms didn’t increase the incidence of high on-treatment platelet reactivity.Keywords
Funding Information
- Miao Pu Fund of Chinese PLA General Hospital (17KMM23)
- Military Healthcare Fund of China (12BJZ39)
This publication has 36 references indexed in Scilit:
- The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantationEuroIntervention, 2013
- Poor Reproducibility of Allergic Rhinitis SNP AssociationsPLOS ONE, 2013
- Diabetes and Antiplatelet Therapy in Acute Coronary SyndromeCirculation, 2011
- Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysisThe Lancet, 2010
- Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future DirectionsDiabetes Care, 2009
- Infliximab treatment shifts the balance between stimulatory and inhibitory Fcγ receptor type II isoforms on neutrophils in patients with rheumatoid arthritisArthritis & Rheumatism, 2008
- Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJournal of Thrombosis and Haemostasis, 2007
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Clopidogrel for Coronary StentingCirculation, 2003
- Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitusBritish Journal of Haematology, 2003